

## Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR)

Maurizio Provenzano\*<sup>1</sup>, Simone Mocellin<sup>2</sup>, Paola Bonginelli<sup>1,4</sup>, Dirk Nagorsen<sup>1</sup>, Seog-Woon Kwon<sup>3</sup> and David Stroncek<sup>1</sup>

Address: <sup>1</sup>Molecular Immunology section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA, <sup>2</sup>Surgery Branch, Department of Oncological and Surgical Science, University of Padova, Italy, <sup>3</sup>Blood Banks, Department of Medicine, Asan Medical Center, Seoul, Korea and <sup>4</sup>Current address: Department of Oncology, Division of Medical Oncology, San Filippo Neri, Via Martinotti 20, 00135, Rome, Italy

Email: Maurizio Provenzano\* - [mprovenzano@mail.cc.nih.gov](mailto:mprovenzano@mail.cc.nih.gov); Simone Mocellin - [mocellins@hotmail.com](mailto:mocellins@hotmail.com); Paola Bonginelli - [paolabonginelli@yahoo.com](mailto:paolabonginelli@yahoo.com); Dirk Nagorsen - [dnagorsen@mail.cc.nih.gov](mailto:dnagorsen@mail.cc.nih.gov); Seog-Woon Kwon - [swkwon@amc.seoul.kr](mailto:swkwon@amc.seoul.kr); David Stroncek - [dstroncek@dtm.cc.nih.gov](mailto:dstroncek@dtm.cc.nih.gov)

\* Corresponding author

Published: 15 December 2003

Received: 27 October 2003

*Journal of Translational Medicine* 2003, **1**:12

Accepted: 15 December 2003

This article is available from: <http://www.translational-medicine.com/content/1/1/12>

© 2003 Provenzano et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

The identification and characterization of viral epitopes across the Human Leukocyte Antigen (HLA) polymorphism is critical for the development of active-specific or adoptive immunotherapy of virally-mediated diseases. This work investigates whether cytokine mRNA transcripts could be used to identify epitope-specific HLA-restricted memory T lymphocytes reactivity directly in fresh peripheral blood mononuclear cells (PBMCs) from viral-seropositive individuals in response to *ex vivo* antigen recall. PBMCs from HLA-A\*0201 healthy donors, seropositive for Cytomegalovirus (CMV) and Influenza (Flu), were exposed for different periods and at different cell concentrations to the HLA-A\*0201-restricted viral FluM1<sub>58-66</sub> and CMVpp65<sub>495-503</sub> peptides. Quantitative real time PCR (qRT-PCR) was employed to evaluate memory T lymphocyte immune reactivation by measuring the production of mRNA encoding four cytokines: Interferon- $\gamma$  (IFN- $\gamma$ ), Interleukin-2 (IL-2), Interleukin-4 (IL-4), and Interleukin-10 (IL-10). We could characterize cytokine expression kinetics that illustrated how cytokine mRNA levels could be used as *ex vivo* indicators of T cell reactivity. Particularly, IFN- $\gamma$  mRNA transcripts could be consistently detected within 3 to 12 hours of short-term stimulation in levels sufficient to screen for HLA-restricted viral immune responses in seropositive subjects. This strategy will enhance the efficiency of the identification of viral epitopes independently of the individual HLA phenotype and could be used to follow the intensity of immune responses during disease progression or in response to *in vivo* antigen-specific immunization.

### Introduction

T cell-directed active or adoptive immunotherapy is an emerging treatment option for chronic viral infections, virally-mediated diseases, and virally-induced cancers.

Several virally-induced cancers are caused by relatively common latent viral infections. Epstein Barr Virus (EBV) can induce post-transplant lymphoma [1], Burkitt's lymphoma, Hodgkin's disease [2], and nasal pharyngeal

carcinoma [3]. Simian virus 40 (SV40) has been associated with mesothelioma [4,5] and Human Papilloma Virus (HPV) with cervical cancer [6] and it appears that T cell reactivity may control their growth. Thus, we have been interested in tools that allow for a simplified and flexible screening of relevant anti-viral immune responses in seropositive subjects. Among such methods we found particularly suitable the detection of cytokine mRNA levels produced by immune cells in response to viral-epitope stimulation. This method involves the detection of cytokine mRNA levels after a short-term *ex vivo* sensitization of peripheral blood mononuclear cells (PBMCs) from seropositive individuals exposed to human leukocyte antigens (HLA)-associated viral-epitopes. Cytokine transcript levels were assessed by quantitative real-time PCR (qRT-PCR). Others have used a similar approach to monitor the kinetics of cytokine induction following polyclonal epitope activation [7,8]. Cytokine transcript measurement by qRT-PCR has also been used to determine the cytokine profile of tumor microenvironment [9] or to monitor cancer-specific immune responses [10]. Kamula et al. pioneered cytokine transcript monitoring by investigating cytokine mRNA expression by melanoma antigen-specific CD8+ T cells in melanoma metastases from patients undergoing epitope-specific vaccination [11]. Recently, cytokine level assessment by qRT-PCR has been used to monitor immune response to other tumors such as soft tissue limb sarcomas after loco-regional therapy [12]. Although the assessment of cytokine production by lymphocytes following stimulation with viral peptides has been characterized after long term *in vitro* cell culture [13], the direct *ex vivo* reactivation of memory T lymphocytes from seropositive healthy donors exposed to HLA-associated viral epitopes has not been fully characterized [14,15]. Direct *ex vivo* sensitization has several advantages over *in vitro* assays; it is simpler and independent of biases introduced by exposing immune cells to arbitrary doses of growth factors routinely used in culture such as Interleukin-2. This assay is a direct quantitative estimate of the immune reactivity toward a given epitope. A subtle but more important advantage of *ex vivo* testing of immune reactivity consists in the identification of easily detectable immune specificities likely to be immunodominant in the context of a given disease and HLA phenotype. Thus, such strategy should be considered an easy screening tool for the identification and characterization of immunodominant epitopes that can be readily applied to any individual independently of HLA phenotype through the utilization of overlapping peptide libraries.

The aim of this study was to characterize the usefulness of cytokine mRNA determination following exposure of PBMCs from human viral-seropositive to relevant epitopes in determining individual immune competence to known immunodominant determinants. Peptides

from Influenza A virus matrix protein M1 (FluM1<sub>58-66</sub>) [16], Cytomegalovirus matrix protein 65 (CMVpp65<sub>495-503</sub>) [17], and from the Tumor Associate Antigen (TAA) Mage-12 (Mage12<sub>170-178</sub>) [18] were used to analyze peptide-specific T cell memory reactivation in three HLA-A\*0201 homozygous healthy donors. The short-term kinetics of Interferon- $\gamma$  (IFN- $\gamma$ ), Interleukin-2 (IL-2), Interleukin-4 (IL-4), and Interleukin-10 (IL-10) were determined by measuring qRT-PCR amplification products. Monitoring of cytokine mRNA production was performed at different time points (from 3 to 48 hours), to select the cytokine with the consistently higher mRNA expression level within the shortest period and to compare this molecular response to short-term protein production evaluated by flow cytometry and ELISA.

The study found that mRNA cytokine analysis of seropositive subjects after *ex vivo* viral and/or tumor peptide exposure is a simple and valid alternative to other methods that test epitope-induced T lymphocyte reactivation. The simplicity and sensitivity of this method in identifying immune dominant epitopes makes it suitable for the investigation of clinically relevant T cell response.

## Material and Methods

### Peptide synthesis, reconstitution and storage

The HLA-A\*0201-restricted Influenza A virus matrix protein M1<sub>58-66</sub> peptide (FluM1<sub>58-66</sub>, GILGFVFTL), the HLA-A\*0201-restricted CMV phosphorylated matrix protein 65<sub>495-503</sub> peptide (CMVpp65<sub>495-503</sub>, NLVPMVATV), and the HLA-Cw\*0702-restricted irrelevant peptide Mage-12 (Mage12<sub>170-178</sub>, VRIGHLYIL), were synthesized with a purity from 90 to 100% as determined by High Pressure Liquid Chromatography (HPLC) analysis (Princeton Biomolecules, Langhorne, PA, USA). Each peptide was dissolved in 25% dimethyl sulfoxide (DMSO) at the final concentration of 1 mg/mL. Up to 50% DMSO was added to those mixtures of peptide that did not dissolve immediately. The peptide solutions were stored at 4°C and replaced every month.

### Donor Selection

After obtaining informed consent, a lymphapheresis was performed on four healthy subjects at the Department of Transfusion Medicine (DTM), Warren G. Magnuson Clinical Center (CC), NIH, Bethesda, Maryland using a CS3000 Plus blood cell separator (Fenwal, Baxter Healthcare Corporation, Deerfield, IL). All donors were HLA-A\*0201 homozygous. High resolution HLA class I genotyping was performed by sequence-specific PCR using genomic DNA (HLA Laboratory, DTM, CC, NIH, Bethesda, MD). The presence of IgG and IgM CMV antibodies in each donor was analyzed by passive latex agglutination (CMVSCAN kit, Becton Dickinson Microbiology System, Cockeysville, MD). Two of the three donors were

seropositive for CMV. The donors were not tested for antibodies to Influenza A since almost all individuals are seropositive.

#### **Preparation of PBMCs for qRT-PCR kinetic by ex vivo sensitization (EVS)**

PBMCs from apheresis products were separated from red blood cells and platelets by Ficoll (Pharmacia Biotech, Wilkstrom, Sweden) density gradient centrifugation. To eliminate residual erythrocytes, an ACK Lysis Buffer (Bio Whittaker, Walkersville, MD) at 1:10 dilution was used while platelets were removed by washing cells twice in HBSS (Biofluid, Rockville, MD) at 800 RPM for 10 min. For the short-term qRT-PCR assays, immediately after PBMCs were isolated, cells were plated in a 96 U-bottom well plate with RPMI (Biofluid, Rockville, MD) complete medium (10% human serum, Gemini Bio-Products, Woodland, CA; supplemented with 1% HEPES, Biofluid) at concentrations of  $1 \times 10^5$ ,  $2 \times 10^5$ ,  $1 \times 10^6$ ,  $2 \times 10^6$  cells/200 $\mu$ l (starting concentrations of  $5 \times 10^5$ ,  $1 \times 10^6$ ,  $5 \times 10^6$ ,  $1 \times 10^7$  cell/ml).  $2 \times 10^5$  cells/200 $\mu$ l has been considered the standard concentration of cells enable to produce a significant amount of IFN- $\gamma$  transcripts, as previously reported [11] The cells were incubated overnight (18 hours) at 37°C (humidity 90%, CO<sub>2</sub> 5%) to minimize background expression of cytokine due to lymphocyte manipulation. The next day, the PBMCs were directly exposed to individual peptides at a final concentration of 1  $\mu$ l/mL and incubated at 37°C from 3 to 48 hours according to experimental conditions. After each incubation period the cells were harvested and used for the measurement of cytokine transcription by qRT-PCR following total RNA extraction and cDNA synthesis.

#### **Total RNA extraction**

After incubation, cells were harvested, washed, and total RNA was extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA) following the manufacturer's instructions. To optimize lysis and homogenization when greater than or equal to  $1 \times 10^7$  cells were tested, 700  $\mu$ l of lysis buffer was used. Total RNA was eluted from columns into a final volume of 30  $\mu$ l RNase free water and stored at -80°C or immediately used for cDNA synthesis.

#### **Complementary DNA synthesis**

One to 5  $\mu$ g total RNA stored at -80°C or rested at 4°C (on ice) immediately after extraction were transcribed into cDNA using the SuperScript pre-amplification system (Invitrogen, Carlsbad, CA). Briefly, total RNA was heated at 70°C for 10 minutes with 1  $\mu$ l oligo (dT) primers (0.5  $\mu$ g/ $\mu$ l) in a final volume of 12  $\mu$ l. After cooling samples at 4°C for 1 min, 7  $\mu$ l of RT-PCR mixture (2  $\mu$ l 10 $\times$  RT Buffer, 2  $\mu$ l 25 mmol of MgCl<sub>2</sub>, 1  $\mu$ l dNTP 10 mmol, and 2  $\mu$ l 1 M DTT) were added to samples. They were held at 42°C for 5 min. Then, 1  $\mu$ l Superscript RT II (50 U/ $\mu$ l) was

added to each sample (final volume 20  $\mu$ l) and cDNA synthesis was performed using these PCR parameters: 42°C for 50 min and 70°C for 15 min. The samples were thus held at 37°C for 20 min with 1  $\mu$ l RNase to avoid RNA contamination. Synthesized cDNA was stored at -20°C until use.

#### **Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)**

Measurement of cytokine mRNA expression by qRT-PCR was performed utilizing an ABI prism 7900 Sequence Detection System (Applied Biosystem, Foster City, CA). IFN- $\gamma$  IL-2, IL-4, IL-10, and  $\beta$ -actin genes primers and TaqMan probes (Applied Biosystem, Foster City, CA) (Table 1) [9,19] were designed to span exon-intron junctions in order to prevent amplification of genomic DNA and to produce amplicons <150 base pairs (bp) enhancing the efficiency of PCR amplification. TaqMan probes were labeled at the 5'-end with the reporter dye molecule FAM (6-carboxyfluorescein; emission  $\lambda_{\max}$  = 518 nm) and at the 3'-end with the quencher dye molecule TAMRA (6-carboxytetramethylrhodamine; emission  $\lambda_{\max}$  = 582 nm). In order to create a standard curve, the cDNA was generated by reverse transcription using a technique identical with the one used for the preparation of test cDNA. Thereafter, cDNA of IFN- $\gamma$  IL-2, IL-4, IL-10, and  $\beta$ -actin genes was amplified by means of regular PCR using the same primers designed for the qRT-PCR and following these parameters: 10 min at 95°C (1 cycle), 30 sec at 95°C, 30 sec at 60°C and 2.5 min at 72°C (40 cycles) and 5 min at 72°C (1 cycle); final volume 50  $\mu$ l. Amplified cDNA was then purified and quantitated by spectrophotometry (OD260). The number of cDNA copies was calculated using the molecular weight of each gene amplicon. Serial dilutions of the amplified gene at known concentrations were tested by qRT-PCR. Quantitative RT-PCR reactions of cDNA specimens and cDNA standards were conducted in a total volume of 50  $\mu$ l with 1 $\times$  TaqMan Master Mix (Applied Biosystem, Foster City, CA) and primers and probes at optimized concentrations (primer 400 nmol and probe 200 nmol) in a 96-well optical reaction plate (Applied Biosystem, Foster City, CA). Thermal cycler parameters were 2 min at 50°C, 10 min at 95°C, and 40 cycles involving denaturation at 95°C for 15 sec and annealing/extension at 60°C for 1 min; final volume 50  $\mu$ l. Real time monitoring of fluorescent emission from the cleavage of sequence specific probes by the nuclease activity of Taq polymerase allowed definition of the threshold cycle during the exponential phase of amplification. Standard curves generated for IFN- $\gamma$  IL-2, IL-4, IL-10, and  $\beta$ -actin genes were found to have excellent PCR amplification efficiency (90–100%; 100% indicates that after each cycle the amount of template is doubled) as determined by the slope of the standard curves. Linear regression analysis of all standard curves was > 0.99. Standard curve

**Table 1: Quantitative real time PCR primers and probes for evaluating the four cytokines of interest and the reference genes.**

Gene	Primers and Probe
$\beta$ -actin	(f) 5'-GGCACCCAGCACAAATGAAG-3' (r) 5'-GCCGATCCACACGGAGTACT-3' (p) 6FAM-TCAAGATCATTGCTCCTCCTGAGAGCGC-TAMRA
IFN- $\gamma$	(f) 5'-AGCTCTGCATCGTTTTGGGTT-3' (r) 5'-GTTCCATTATCCGCTACATCTGAA-3' (p) 6FAM-TCTTGGGCTGTTACTGCCAGGACCCA-TAMRA
IL-2	(f) 5'-ACCAGGATGCTCACATTTAAGTTTT-3' (r) 5'-GAGGTTTGAGTTCTTCTTCTAGACACTG-3' (p) 6FAM-CATGCCCAAGAAGGCCACAGAAGT-TAMRA
IL-4	(f) 5'-GCGATATCACCTTACAGGAGATCAT-3' (r) 5'-GTTACGGTCAACTCGGTGCA-3' (p) 6FAM-TGCTGCCAACTGGCGCTCCTCC-TAMRA
IL-10	(f) 5'-GCCGTGGAGCAGGTGAAG-3' (r) 5'-GAAGATGTCAAACCTCACTCATGGCT-3' (p) 6FAM-TGCCTTAATAAGCTCCAAGAGAAAGGCATCTACA-TAMRA

(f) forward primer; (r) reverse primer; (p) probe \* These primers and probes have been previously published [9,19]

extrapolation of gene copy number was performed for all genes studied. Normalization of values was performed by dividing the copies of the genes of interest (IFN- $\gamma$ , IL-2, IL-4 and IL-10) by the copies of the reference gene ( $\beta$ -actin). All standard and sample PCR assays were performed in triplicate and reported as the average.

#### **Intracellular staining (ICS) assay**


Freshly isolated PBMCs from seropositive donors at a concentration of  $1.5 \times 10^6$  cells/ml of RPMI complete medium (without HEPES, Biofluid, Rockville, MD) were rested overnight in a 14 mL polypropylene tube (Becton Dickinson, Franklin Lakes, NJ) and then stimulated with peptide at a final concentration of 10  $\mu$ g/mL each tube. One hour after cell activation, Brefeldin A (Sigma, Saint Louis, MI) at a final concentration of 10  $\mu$ g/mL was added to each tube culture. After 5 more hours (6 hours total) cells were transferred to 5 mL polystyrene round bottom tubes (Becton Dickinson, Franklin Lakes, NJ) and cell incubation was stopped washing cells in 2 mL cold PBS for 5 min (1500, 4°C). Pellets were re-suspended in 1 mL PBS containing 1 mmol EDTA and tubes were incubated at 37°C for 10 min to detach adherent cells. After washing cells with 2 mL cold FACS buffer (PBS plus 0.5%BSA) by centrifugation (5 min, 1500, 4°C), cells were maintained in a 100 mL suspension for monoclonal antibodies (MoAb) extra-cellular staining. Cells were stained with 10  $\mu$ l of CD3-PE and 10  $\mu$ l CD8-PerCP (BD, Bioscience, San Jose, CA) for 15 min at 4°C (on ice) in the dark. After surface staining, 2 mL of BD FACS Lysing Solution (BD, Bioscience, San Jose, CA) at 1:10 dilution in PBS was added to each tube and the cells were washed by centrifugation (5 min, 1500, 4°C). Permeabilization of cells was performed by re-suspending cells in 500  $\mu$ l of FACS Permea-

bilizing Solution 2 (BD, Bioscience, San Jose, CA) at 1:10 dilution in DEPC water, vortexing them for 30 sec and incubating them at room temperature (RT) for 10 min. The cells were thus washed twice by centrifugation (2 mL cold FACS Buffer, 5 min, 1500, 4°C). For intracellular staining, the cells were stained with either 20  $\mu$ l of human anti IFN- $\gamma$ -FITC or mouse IgG<sub>1</sub> isotype-FITC (BD, Bioscience, San Jose, CA) and incubated for 30 minutes at 4°C (on ice) in the dark. After staining, the cells were washed once (2 mL cold FACS Buffer, 10 min, 1500, 4°C) and immediately analyzed on a flow cytometer or fixed in 200  $\mu$ l 4% paraformaldehyde in PBS solution, kept at 4°C in the dark and analyzed later.

#### **Peptide-specific ex vivo (EVS) and in vitro sensitization (IVS) for protein release kinetics**

Cell supernatants from *ex vivo* stimulated PBMCs sensitized at different concentrations and times of exposure were used for the measurement of cytokine protein release with an enzyme-linked immunoabsorbent assay (ELISA) kit (Endogen, Woburn, MA). Briefly, after each time point harvested cells were used for mRNA cytokine transcription while supernatant were used for protein release detection.

In parallel, a 2-week *in vitro* sensitization was performed using PBMCs from CMV-seropositive donors. Cells were plated at a concentration of  $3 \times 10^6$ /2 ml of medium per well in a anti-human CD3 T-cell activation 24-well plate (Becton Dickinson, Bedford, MD) and directly stimulated with 3  $\mu$ l/mL of peptide (day 0). One day later (day 1), recombinant human interleukin-2 (rhIL-2, 100 U/ml) and recombinant human interleukin-7 (rhIL-7, 10 ng/ml) (PeproTech, Rocky Hill, NJ) were added to the cell culture. rhIL-2 only (100 U/ml) was continuously administered

**Figure 1**

**The kinetics of IFN- $\gamma$ , IL-2, IL-4 and IL-10 transcription following FluM1<sub>58-66</sub> stimulation of three HLA-A\*0201 donors.** The standard concentration of  $2 \times 10^5$  cells/200  $\mu$ l was *ex vivo* exposed to the peptide. At hour 3, IFN- $\gamma$  transcript production precedes IL-2, IL-4 and IL-10. At hour 12 there is consistent production of T<sub>h</sub>1 (IFN- $\gamma$ , IL-2) cytokines. IL-4 and IL-10 transcript production increases above the baseline levels from 24 to 48 hours. For each donor and at each time point mRNA copy numbers were calculated relative to unstimulated cells after normalization by  $\beta$ -actin. The result represents the mean  $\pm$  SEM of averages of combined values of three independent experiments carried out on each of the three donors.

every other day. At day 15, each group of cells was washed and directly re-stimulated in 2 mL of fresh medium with 3  $\mu$ l/mL of peptide or was not re-stimulated. Eighteen hours after peptide boosting, the *in vitro* sensitized PBMCs were harvested. Supernatants were collected to measure IFN- $\gamma$  protein release using the ELISA assay.

#### Data analysis


Quantitative RT-PCR results were reported as the number of IFN- $\gamma$ , IL-2, IL-4, and IL-10 gene copies normalized by  $10^5$   $\beta$ -actin gene copies and plotted against the different times of exposure. The cytokine production, as shown, represents the mRNA copy number of the gene of interest from stimulated cells relative to the copy number of the gene of interest from unstimulated cells, in both cases after normalization by the gene of reference ( $\beta$ -actin). Figure 3 shows the results as mRNA copy numbers corrected by  $\beta$ -actin. Student's t test was used to compare cytokine mRNA release as well as cytokine protein expression by PBMCs stimulated under different conditions. ELISA results were extrapolated from a standard curve generated

by linear regression. Three-color flow cytometry was performed using a FACS-Calibur flow cytometer and data were analyzed using CellQuest software. For each analysis, 250,000 events were acquired. A light scatter region was designed to include only viable lymphocytes. FACS analysis was performed on gated CD3<sup>bright</sup> expression allowing the exclusion of residual contaminating cells.

#### Results

##### Quantification of human IFN- $\gamma$ , IL-2, IL-4, and IL-10 mRNAs after *ex vivo* epitope stimulation of PBMCs

To determine the best target cytokine for assessing epitope-specific memory T lymphocytes reactivation, gene amplification of four cytokine, IFN- $\gamma$ , IL-2, IL-4, and IL-10 was estimated by qRT-PCR. Cytokine mRNA levels were measured over 48 hours following *ex vivo* peptide exposure of PBMCs from three HLA-A\*0201 subjects. Since approximately 90% of the population has been exposed to Influenza, we initially analyzed the response to the peptide FluM1<sub>58-66</sub> (GILGFVFLT). After 3 hours large quantities of IFN- $\gamma$  transcripts were detected, but little or no IL-2,

**Figure 2**


**IFN- $\gamma$  transcript production by memory T lymphocytes following *ex vivo* FluM1<sub>58-66</sub>, CMVpp65<sub>495-503</sub>, and MageI2<sub>170-178</sub> peptide stimulation.** In the period of 3 to 12 hours, IFN- $\gamma$  cytokine production was inversely proportional to the time of exposure during FluM1<sub>58-66</sub> stimulation (panel A), maintained an average level during CMVpp65<sub>495-503</sub> stimulation (panel B) or was not produced during MageI2<sub>170-178</sub> exposure (panel C). The results are expressed in mRNA copy numbers calculated relative to unstimulated cells after normalization by  $\beta$ -actin and represent the expressed values from each donor tested. Panel D specifically shows the kinetics of a representative donor (donor B) after the different viral peptide exposures relative to the negative value (unstimulated cells).

IL-4, and IL-10. Maximum levels of IL-2 transcripts were detected at hour 24. IL-4 and IL-10 transcripts levels increased above baseline level after 24 hours and continued to rise up to 48 hours from stimulation (Fig 1). Although IFN- $\gamma$  transcript rapidly decreased during the 48 period, significant levels were still detectable at hour 12 in all three donors. These results show that following *ex vivo* peptide stimulation of memory T cells, IFN- $\gamma$  precedes IL-2, IL-4, and IL-10 transcription.

#### **Human IFN- $\gamma$ transcript quantification following stimulation with CMVpp65<sub>495-503</sub>, FluM1<sub>58-66</sub> or MageI2<sub>170-178</sub>**

Since IFN- $\gamma$  transcripts were the earliest and most abundant transcripts, we further characterized IFN- $\gamma$  mRNA expression in response to other *ex vivo* peptide stimula-

tions. The three HLA-A\*0201 donors were stimulated with CMVpp65<sub>495-503</sub> (NLVPMVATV), FluM1<sub>58-66</sub> (GILGFVFTL), and the irrelevant Mage<sub>170-178</sub> (VRIGH-LYIL) peptides. Analysis of the response curves showed that CMV stimulation did not result in the same transcription kinetics of Flu (Fig 2, donor A and B in panel B). IFN- $\gamma$  transcription levels upon Flu stimulation were greatest after 3 hours and showed a linear reduction (Fig 2, panel A). In contrast, IFN- $\gamma$  transcription levels after CMV stimulation varied but did not differ significantly between 3, 6, and 12 hours before falling drastically after 24 hours (Fig 2, panel B). Stimulations of all three donors with the irrelevant Mage<sub>170-178</sub> and stimulation of the CMV-seronegative donor with CMVpp65<sub>495-503</sub> failed to induce IFN- $\gamma$  transcription at any time point (Fig 2, panel C and donor C in panel B).




**Figure 3**

**Effect of cell concentration on the specific kinetics of IFN- $\gamma$  transcript production during CMVpp65<sub>495-503</sub> peptide stimulation.** Different concentrations of PBMCs from two CMV seropositive donors and one CMV seronegative donor were *ex vivo* peptide stimulated and analyzed at hour 3, 12 and 24 of sensitization for IFN- $\gamma$  transcript production. For all donors tested, panels A, B and C show IFN- $\gamma$  transcript production for each time of exposure (hour 3, 12 and 24, respectively) relative to cell concentration. Inversely, panels D, E and F show IFN- $\gamma$  transcription for each quantity of stimulated cells relative to the three times of exposure only for the two seropositive donors. All results represent the mean  $\pm$  SEM of three independent experiments carried out in triplicate.

**Correlation between IFN- $\gamma$  transcription and cell concentration following *ex vivo* CMVpp65<sub>495-503</sub> stimulation of PBMCs from HLA-A\*0201 CMV-seropositive and seronegative donors**

To investigate the reasons for differences observed in the kinetics of IFN- $\gamma$  transcription between CMVpp65<sub>495-503</sub> and FluM1<sub>58-66</sub> peptide stimulation, we tested whether concentration of responded cells could affect such kinetics. Thus, the correlation between IFN- $\gamma$  mRNA production and number of lymphocytes exposed to

CMVpp65<sub>495-503</sub> was explored. PBMCs from all three donors were stimulated *ex vivo* at various concentrations of  $1 \times 10^5$ ,  $2 \times 10^5$ ,  $1 \times 10^6$ ,  $2 \times 10^6$  cells/200 $\mu$ l with CMVpp65<sub>495-503</sub> and evaluated at 3, 12 and 24 hours. We found that at the 3-hour time point IFN- $\gamma$  transcription increased directly with cell concentration (Fig 3, panel A), but after 12 hours IFN- $\gamma$  transcription reached a peak at intermediate concentrations ( $2 \times 10^5$  cells/200 $\mu$ l) (Fig 3, panel B). At hour 24, IFN- $\gamma$  transcription was low and similar at all cell concentrations (Fig 3, panel C). Interestingly

**Figure 4**

**Assessment of the IFN- $\gamma$  protein release kinetics by *ex vivo* peptide-stimulated PBMCs.** Two donors, one CMV seropositive and one CMV seronegative, were exposed at various durations of time to both FluM1<sub>58-66</sub> and CMVpp65<sub>495-503</sub> peptides and cell supernatants were analyzed for IFN- $\gamma$  protein release (panel A and B). Panel C shows the protein release from both FluM1<sub>58-66</sub> and CMVpp65<sub>495-503</sub> 2-week sensitized PBMCs from the CMV seropositive donors either after an 18-hour peptide re-exposure or after no peptide re-exposure. Results represent the mean  $\pm$  SEM of three independent experiments carried out in triplicate.


in this experiment, the kinetics of IFN- $\gamma$  transcription were similar to the results observed previously with CMVpp65<sub>495-503</sub> stimulation (Fig 2, panel B) only when cells were tested at a concentration of  $1 \times 10^5$  (data not shown) and  $2 \times 10^5/200\mu\text{l}$  (Fig 3, panel D). Conversely, the slopes of both curves obtained at concentrations of  $1 \times 10^6$  and  $2 \times 10^6$  cells/ $200\mu\text{l}$  (Fig 3, panel E and F) followed a decreasing IFN- $\gamma$  transcription kinetics similar to that displayed by flu stimulation (Figure 2, panel A).

#### **Extra-cellular and intra-cellular release of IFN- $\gamma$ protein following *ex vivo* peptide-stimulated PBMCs**

To determine if other measures of IFN- $\gamma$  could be used to effectively evaluate T cell activation following *ex vivo* stimulation, the kinetics of IFN- $\gamma$  protein release was assessed. Following various durations of exposure of PBMCs to

either FluM1<sub>58-66</sub> or CMVpp65<sub>495-503</sub>, cell supernatants were analyzed for IFN- $\gamma$  protein release. From 3 through 48 hours after sensitization, IFN- $\gamma$  protein release by PBMCs from the seropositive subjects was not or only slightly different from the protein release by PBMCs from the seronegative subject (Fig 4, panels A and B). In contrast, when the cells were sensitized for 2 weeks and boosted with the same peptides, IFN- $\gamma$  protein production was 10-fold higher, confirming that it is possible to use protein production to estimate the T cell response when *in vitro* cell sensitization is carried out (Fig 4, panel C). Conversely, the IFN- $\gamma$  intra-cellular staining was consistently positive upon *ex vivo* stimulation with CMVpp65<sub>495-503</sub> peptide and moderately positive with FluM1<sub>58-66</sub> peptide (Fig 5). No evidence of intra-cellular protein accumulation was observed at different time points tested



**Figure 5**

**IFN- $\gamma$  Intracellular Staining (ICS) after the standard six hours peptide exposure.** All donors were exposed to both FluM1<sub>58-66</sub> and CMVpp65<sub>495-503</sub> peptides and then analyzed for intracellular IFN- $\gamma$  protein release. Panel A: FACS analysis was conducted on gated CD3 positive lymphocytes after selecting only viable cells (R1 and R2) and plotting CD8 positive (x-axis) against either mouse IgG<sub>1</sub> isotype-stained (y-axis, upper row) or human anti-IFN- $\gamma$ -stained (y-axis, lower row) lymphocytes. The figure shows one representative experiment of three carried out on each donor. Panel B: IFN- $\gamma$  ICS results in 3 different donors. The calculation of the percentage of antigen-specific T cells was performed based on the CD8 and IFN- $\gamma$  dot plot data according to the following formula: Percentage<sub>Ag-specific T-cells</sub> = Percentage<sub>Upper right quadrant</sub> / (Percentage<sub>Upper right quadrant</sub> + Percentage<sub>Lower right quadrant</sub>) \* 100%.

before the standard 6 hour sensitization (data not shown).

## Discussion

Memory T lymphocytes represent a population of active immune effectors that retain a prior stimulus and evoke a stronger and more rapid immune response after a secondary immunization. Among the cytokines produced after immune reactivation, IFN- $\gamma$  is released within a few hours after stimulation. IFN- $\gamma$  is produced in response to antigen-specific stimulation by cytotoxic T lymphocytes (CTLs) and inflammatory CD4+ T cells (T<sub>H</sub>1) and their precursor (T<sub>H</sub>0) or nonspecifically by natural killer (NK) cells [20]. Its levels are an indicator of the immune activity of armed effector T cells.

The evaluation of memory T cell reactivation can be performed between 3 to 12 hours irregardless of the source of peptides. Initially, cytokine mRNA transcription was tested against  $2 \times 10^5$  PBMCs by using FluM1<sub>58-66</sub>. Flu sensitization displayed the greatest rates of IFN- $\gamma$  release 3 hours after stimulation. In spite of the inverse correlation

of the transcript levels to the time of exposure, FluM1<sub>58-66</sub> maintained significant amounts of IFN- $\gamma$  transcription during the 3 to 12 hour period. In contrast, peak IL-2, IL-4 and IL-10 mRNA did not occur until 24 to 48 hours after peptide sensitization. Conversely, CVMpp65<sub>495-503</sub> stimulation displayed different IFN- $\gamma$  mRNA transcription kinetics regardless of cell concentration and periods of exposure. However, studies of the kinetics of expression of the four cytokines revealed that IFN- $\gamma$  mRNA can be detected either after both FluM1<sub>58-66</sub> and CVMpp65<sub>495-503</sub> peptide stimulation between 3 and 12 hours at the standard concentration of  $2 \times 10^5$  cells.

These results suggest that it is possible to vary the time of cell analysis from 3 to 12 hours after peptide stimulation. In some cases it may be necessary to analyze cells more than 3 hours after stimulation due to variations in the interactions between HLA antigens and peptides. Our group has already found that analysis of cells 5 hours after peptide exposure enhanced the ability to detect HLA-A\*0301, A\*3301, and A\*3303 interactions with CMV pp65 peptides [21,22].

Different types of assays have been used to identify CTL specificity by measuring IFN- $\gamma$  protein levels including ELISA, ELISPOT and intracellular staining (ICS). While both ELISA and ELISPOT assays are effective, they have the major disadvantage of requiring that cells are stimulated and cultured for several days or even weeks before monitoring immune T cell activity [23]. Moreover, prolonged cultures of sensitized cells may lead to the artifactual expansion of irrelevant cell populations. Consistent with the fact that a 3-hour sensitization is a short time for mRNA translation and protein production or for the proliferation of a sub-population of responding memory T cells [24,25], we found that protein detection assays failed to detect activated cells when carried out on unexpanded PBMCs demonstrating the higher sensitivity of the technique we used to induce and detect a T cell response after few hours [26-29].

The ancillary use of ICS or IVS protein detection assays to investigate the specific immune activity of potential immunodominant peptides is helpful in completing the understanding of how those peptides work in the context of specific immune reactivation.

In conclusion, we confirmed that molecular analysis by qRT-PCR was effective in identifying immune activity of viral peptides by reactivation of stimulated memory T cell from seropositive HLA-restricted donors after only 3 hours. The secondary immune response resulted in a strong T<sub>H</sub>1 cytokines production (IFN- $\gamma$  and IL-2) within few hours. Negative results obtained following tumor-peptide stimulation of PBMCs from subjects not exposed to tumor antigens or subjects seronegative for the target viral antigens confirmed this finding.

By using this method we were able to confirm the immunogenicity of the peptides FluM1<sub>58-66</sub> and CMVpp65<sub>495-503</sub> [30-32]. The major practical advantage is that it allows the rapid evaluation of immune memory T cells reactivation by the detection of specific cytokine gene profiles. It makes it possible to screen a large number of viral and/or tumor epitopes and to study their immune activity in a short period of time, with high specificity and without handling large quantities of cells. The strong response after viral restimulation and the ability to use seropositive donors make this method valuable for any disease-related viral peptide investigation.

### Abbreviations

APC, antigen presenting cells; CMV, Cytomegalovirus; Flu, Influenza virus; TAA, tumor associated antigens; IVS, in vitro sensitization; EVS, ex vivo sensitization; ICS, intracellular staining; HLA, human leukocyte antigens; PBMC, peripheral blood mononuclear cells

### References

1. Tao Q, Yang J, Huang H, Swinnen LJ, Ambinder RF: **Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy.** *Am J Pathol* 2002, **160**:1839-1845.
2. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM: **Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.** *Blood* 2003, **101**:1905-1912.
3. Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DL, Sham JS, Moss D, Yuen KY, Im SW, Ng MH: **Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma.** *Int J Cancer* 2001, **94**:73-80.
4. Velders MP, Macedo MF, Provenzano M, Elmishad AG, Holzhtutter HG, Carbone M, Kast WM: **Human T cell responses to endogenously presented HLA-A\*0201 restricted peptides of Simian virus 40 large T antigen.** *J Cell Biochem* 2001, **82**:155-162.
5. Bright RK, Kimchi ET, Shearer MH, Kennedy RC, Pass HI: **SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients.** *Cancer Immunol Immunother* 2002, **50**:682-690.
6. Chiriva-Internati M, Liu Y, Salati E, Zhou W, Wang Z, Grizzi F, Roman JJ, Lim SH, Hermonat PL: **Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells.** *Eur J Immunol* 2002, **32**:30-38.
7. Stordeur P, Poulin LF, Craciun L, Zhou L, Schandene L, de Lavarelle A, Goriely S, Goldman M: **Cytokine mRNA quantification by real-time PCR.** *J Immunol Methods* 2002, **259**:55-64.
8. Stordeur P, Zhou L, Byl B, Brohet F, Burny W, de Groote D, van der Poll T, Goldman M: **Immune monitoring in whole blood using real-time PCR.** *J Immunol Methods* 2003, **276**:69-77.
9. Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M: **Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment.** *J Immunol Methods* 2003, **280**:1-11.
10. Panelli MC, Wang E, Monsurro V, Marincola FM: **The role of quantitative PCR for the immune monitoring of cancer patients.** *Expert Opin Biol Ther* 2002, **2**:557-564.
11. Kammula US, Marincola FM, Rosenberg SA: **Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.** *J Natl Cancer Inst* 2000, **92**:1336-1344.
12. Mocellin S, Provenzano M, Lise M, Nitti D, Rossi CR: **Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma.** *Int J Cancer* 2003, **107**:317-322.
13. Trojan A, Urosevic M, Hummerjohann J, Giger R, Schanz U, Stahel RA: **Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR.** *J Immunother* 2003, **26**:41-46.
14. Provenzano M, Mocellin S, Bettinotti M, Preuss J, Monsurro V, Marincola FM, Stroncek D: **Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells.** *J Immunother* 2002, **25**:342-351.
15. Provenzano M, Lim JB, Mocellin S, Monsurro V, Bettinotti M, Marincola FM, Stroncek D: **The matrix protein pp65 341-350, a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A\*2402 or A\*0101 allele.** *Transfusion* 2003, **43**:1567-1574.
16. Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR, Zweerink HJ: **The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2.** *J Immunol* 1991, **147**:4047-4053.
17. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ: **Development of a candidate HLA A\*0201 restricted peptide-based vaccine against human cytomegalovirus infection.** *Blood* 1997, **90**:1751-1767.
18. Lally KM, Mocellin S, Ohnmacht GA, Nielsen MB, Bettinotti M, Panelli MC, Monsurro V, Marincola FM: **Unmasking cryptic epitopes**

- after loss of immunodominant tumor antigen expression through epitope spreading. *Int J Cancer* 2001, **93**:841-847.
19. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM: **Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens.** *J Immunol* 1999, **163**:6867-6875.
  20. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A: **Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.** *J Exp Med* 1998, **187**:875-883.
  21. Lim JB, Bettinotti M, Caruccio L, Nagorsen D, Stroncek D, Provenzano M: **Identification of three different CMV epitopes as common target antigens for HLA-A\*0301 restricted CMV-specific cytotoxic T lymphocytes [abstract].** *Blood* 2002, **99**:s3293.
  22. Lim JB, Provenzano M, Bettinotti M, Caruccio L, Nagorsen D, Stroncek D: **Identification of a new HLA-A\*3301 and HLA-A\*3303 restricted cytomegalovirus-specific CD8+ T lymphocytes epitope [abstract].** *Blood* 2003, **102**:s2677.
  23. Pittet MJ, Zippelius A, Speiser DE, Assenmacher M, Guillaume P, Valmori D, Lienard D, Lejeune F, Cerottini JC, Romero P: **Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.** *J Immunol* 2001, **166**:7634-7640.
  24. Kern F, Surel IP, Brock C, Freistedt B, Radtke H, Scheffold A, Blasczyk R, Reinke P, Schneider-Mergener J, Radbruch A, Walden P, Volk HD: **T-cell epitope mapping by flow cytometry.** *Nat Med* 1998, **4**:975-978.
  25. Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA, Marincola FM: **Functional heterogeneity of vaccine-induced CD8(+) T cells.** *J Immunol* 2002, **168**:5933-5942.
  26. Tesfa L, Volk HD, Kern F: **Comparison of proliferation and rapid cytokine induction assays for flow cytometric T-cell epitope mapping.** *Cytometry* 2003, **52A**:36-45.
  27. Prussin C: **Cytokine flow cytometry: understanding cytokine biology at the single-cell level.** *J Clin Immunol* 1997, **17**:195-204.
  28. Mascher B, Schlenke P, Seyfarth M: **Expression and kinetics of cytokines determined by intracellular staining using flow cytometry.** *J Immunol Methods* 1999, **223**:115-121.
  29. Listvanova S, Temmerman S, Stordeur P, Verscheure V, Place S, Zhou L, Locht C, Mascart F: **Optimal kinetics for quantification of antigen-induced cytokines in human peripheral blood mononuclear cells by real-time PCR and by ELISA.** *J Immunol Methods* 2003, **281**:27-35.
  30. Cebon J, Jager E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W, Gibbs S, Chen Q, Karbach J, Jackson H, MacGregor DP, Sturrock S, Vaughan H, Maraskovsky E, Neumann A, Hoffman E, Sherman ML, Knuth A: **Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.** *Cancer Immunol* 2003, **3**:7.
  31. Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, Craddock C, Moss PA: **Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.** *Blood* 2001, **97**:1232-1240.
  32. Peggs K, Verfuert S, Mackinnon S: **Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions.** *Blood* 2001, **97**:994-1000.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

